Chris Molloy to lead Medicines Discovery Catapult

Chris Molloy to lead Medicines Discovery Catapult

Chris Molloy has been named as the first chief executive of the Medicines Discovery Catapult based at Alderley Park.

The government’s Medicines Discovery Catapult aims to shape drug discovery and development in the UK and help others to do the same.

Molloy is currently chief executive at the RSA Group, a leading global life sciences executive search and management specialist.

He has significant senior level experience across pharmaceuticals, biotechnology, informatics and start-up sectors, and will take up his new post in November.

He said: “Fundamental to the catapult’s mission will be the fact that great people make great R&D, something I have seen throughout my career and recently in advising RSA’s global clients.

“The catapult will engage the UK’s experienced drug discovery talent and help launch a new generation of drug R&D leaders into a successful future.

“It is an incredibly exciting and forward-thinking organisation that will actively shape the direction of travel in drug discovery and development and enable others in the UK to do so too.”

Chief executive of Innovate UK, Dr Ruth McKernan, added: “This is an excellent appointment for the Medicines Discovery Catapult.

“Chris’s long-standing experience and expertise in the international life sciences sector will be invaluable to the Catapult’s development, and I look forward to working closely with him.”

Chris began his drug discovery career at Glaxo and was instrumental in helping to deliver specialist automation and informatics systems that had a significant impact on research.

He is also a former chief operating officer at MerLion Pharmaceuticals and a former vice-president corporate development and marketing at IDBS.